Remedy Entertainment PLC (OTCPK:RMDEF)

Q4 2025 Remedy Entertainment Oyj Earnings Call Transcript

Feb 10, 2026 / 10:00 AM GMT

Release Date Price: $16.76

Transcript

Key Points

Positve

Remedy Entertainment PLC (RMDEF) reported a significant revenue growth of 17% for the full year 2025, reaching €59.5 million.
The company successfully unveiled 'Control Resonant,' a sequel to the award-winning game 'Control,' with positive community reception and increased wish listings.
45% of the company's revenue in 2025 came from game sales and royalties, marking a strategic shift towards self-publishing and sales.
The company achieved over 5 million lifetime sales of the original 'Control' game, indicating strong brand interest.
Remedy Entertainment PLC (RMDEF) is on track to deliver a steady cadence of releases, aiming for one game per year with the current scale and operations.

Negative

The company's EBIT for the full year 2025 was significantly negative at €50 million, largely due to a €14.9 million impairment related to FPC Firebreak.
Cash flow was negative in Q4 2025, with operating cash flow at €-3.3 million, impacted by timing differences in sales-related payments.
Despite positive reception, the numbers for FPC Firebreak remain low and stable, indicating limited commercial success.
The company experienced a decline in development fees compared to the previous year, affecting overall revenue growth.
Remedy Entertainment PLC (RMDEF) faced challenges with a weak USD rate, negatively impacting revenue growth in Q4 2025.

Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

REMEDY.HE - Remedy Entertainment Oyj
Q4 2025 Remedy Entertainment Oyj Earnings Call
Feb 10, 2026 / 10:00AM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
Ladies and gentlemen, the Remedy Investors, welcome to the webcast for Remedies full year Results of 2025. My name is Apo Kilpinan from Remedies Investor Relations. Joining with me today are Remedies interim CEO Marcus Becky and Remedies CFO Santo Kaoppa.

Marcos will guide us through the quarter in the full year and then Santo will dive deeper into the financials. We'll then look at the outlook for 2026 before moving to the Q&A session at the end of the webcast. If you have any questions, feel free to leave those already at the text box below the webcast. But without further ado, Marcos, please, how did the quarter go?

--------------------------------------------------------------------------------

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.